Search results
Showing 7441 to 7455 of 8314 results
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia (DG2)
Both index tests included in this guidance are no longer commercially available. Therefore the guidance has been withdrawn.
July 2022: The guidance has been withdrawn because PCR tests now form part of standard care. Since the diagnostics guidance was published, expert advice suggests that clinical practice has moved on; PCR testing using a centralised approach is widely available in the NHS and adoption is growing. The UK standards for Microbiology Investigation also provide additional support for the PCR-based diagnostic tests.
Irreversible electroporation for treating pancreatic cancer (IPG442)
Interventional procedures, IPG442 - Issued: February 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 579.
Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 711.
Interventional procedures, IPG454 - Issued: April 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 603.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG447)
Interventional procedures, IPG447 - Issued: March 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 478.
Sutureless aortic valve replacement for aortic stenosis (IPG456)
Interventional procedures, IPG456 - Issued: July 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 624.
Interventional procedures, IPG479 - Issued: February 2014 --> This guidance has been updated and replaced by NICE interventional procedures guidance 631.
Insertion of endobronchial valves for lung volume reduction in emphysema (IPG465)
Interventional procedures, IPG465 - Issued: September 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 600.
Interventional procedures, IPG51 - Issued: March 2004 --> This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Transcatheter valve-in-valve implantation for aortic bioprosthetic valve dysfunction (IPG504)
Interventional procedures, IPG504 - Issued: September 2014 --> This guidance has been updated and replaced by NICE interventional procedures guidance 653.
Endovascular aneurysm sealing for abdominal aortic aneurysm (IPG547)
March 2019: We have withdrawn the guidance because the CE mark for the Nellix Endovascular Aneurysm Sealing (EVAS) System has been withdrawn. Endologix is recalling unused stock. The MHRA recommends enhanced patient surveillance (see MDA/2019/002) because of a high risk of the graft failing beyond 2 years after implantation.
This guidance has been updated and replaced by NICE interventional procedures guidance 796.
Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
This guidance has been updated and replaced by NICE interventional procedures guidance 762.